Furthermore, when RAC1 expression was evaluated for prognosis, the results showed that Ann Arbor Stage I to II lymphoma patients—who would have better survival—had higher expression levels of RAC1 than those patients who were defined to develop to stage III to IV, thus indicating that DLBCL patients with higher RAC1 expression lived longer. This evidence concerns the gene RAC1 and lymphoma.